Targeting senescent cells in post-traumatic osteoarthritis: mechanisms, microenvironment remodeling, and

Jipeng E1, Qiang E1, Guangsan Zhou1

  • 1Suihua First Hospital, Suihua City, China.

Peerj
|March 23, 2026
PubMed
Abstract

Insights

Targeting senescent cells offers a promising treatment for post-traumatic osteoarthritis (PTOA). Eliminating these cells or their inflammatory secretions can reduce cartilage damage and pain, paving the way for new PTOA therapies.

Area of Science:

  • Biomedical Science
  • Cellular Biology
  • Osteoarthritis Research

Background:

  • Post-traumatic osteoarthritis (PTOA) rapidly develops after joint injuries, often affecting young adults.
  • Cellular senescence and its associated secretory phenotype (SASP) are increasingly implicated in PTOA pathogenesis.
  • Mechanisms linking trauma-induced senescence to cartilage degeneration require further elucidation.

Purpose of the Study:

  • To review emerging evidence on senescence-targeted strategies for PTOA.
  • To contextualize trauma-induced senescence within broader aging and osteoarthritis paradigms.
  • To explore advanced therapeutic approaches for PTOA.

Main Methods:

  • Synthesis of current research on senescence and PTOA.
  • Analysis of pathways activated by joint injury (e.g., DNA damage, oxidative stress).
  • Review of pre-clinical findings on senolytic and anti-SASP interventions.

Main Results:

  • Joint injury triggers senescence in chondrocytes and synovial cells via pathways like p53/p21 and p16 INK4a.
  • Senescent cells release SASP, accelerating cartilage degradation, bone remodeling, and further senescence.
  • PTOA exhibits rapid, localized senescence, distinct from age-related osteoarthritis.
  • Pre-clinical studies show senescent cell elimination or SASP inhibition reduces cartilage damage and pain.

Conclusions:

  • Targeting cellular senescence presents a promising disease-modifying strategy for PTOA.
  • Clinical translation necessitates optimized delivery, timing, and biomarker development.
  • Advanced therapies like nanoparticles and gene vectors show potential for targeted senescent cell intervention.